0 227

Cited 4 times in

Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)

Authors
 Bum Jun Kim  ;  Hee-Jung Jee  ;  Sun Young Rha  ;  Hye Sook Han  ;  Min-Hee Ryu  ;  Se Hoon Park  ;  Jong Gwang Kim  ;  Woo Kyun Bae  ;  Keun-Wook Lee  ;  Do-Youn Oh  ;  Ji-Hye Byun  ;  Dong Sook Kim  ;  Young Ju Suh  ;  Hyonggin An  ;  Dae Young Zang 
Citation
 GASTRIC CANCER, Vol.25(3) : 609-618, 2022-05 
Journal Title
GASTRIC CANCER
ISSN
 1436-3291 
Issue Date
2022-05
MeSH
Adenocarcinoma* / pathology ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols / therapeutic use ; Esophageal Neoplasms ; Esophagogastric Junction / pathology ; Humans ; Paclitaxel / therapeutic use ; Republic of Korea ; Stomach Neoplasms* / pathology
Keywords
ErbB-2 ; Paclitaxel ; Ramucirumab ; Stomach neoplasms
Abstract
Background A subgroup analysis of data from a nationwide study (KCSG-ST19-16) was performed to evaluate the efficacy and safety of second-line ramucirumab plus paclitaxel treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma. Methods The KCSG-ST19-16 study enrolled a total of 1063 patients from 56 hospitals in South Korea with advanced gastric or GEJ adenocarcinoma, who had received second-line treatment with ramucirumab plus paclitaxel. HER2 status was known for 994 (93.5%) of these patients, who were thus included in the subgroup analysis. Results In total, 163 of 994 patients (16.4%), had HER2-positive gastric or GEJ adenocarcinoma. The objective response rate to ramucirumab plus paclitaxel treatment was significantly higher in patients with HER2-positive disease compared to those with HER2-negative disease (23.0% [95% confidence interval (CI), 15.9-30.1] vs. 15.1% [95% CI, 12.3-17.9], p = 0.025). The median progression-free survival was longer in patients with HER2-positive versus HER2-negative disease, but the difference was not statistically significant (4.3 months [95% CI, 3.7-5.3] vs 3.7 months [95% CI, 3.4-4.0], p = 0.054). There was no statistically significant difference in median overall survival (OS) between the groups (9.8 months [95% CI, 8.9-12.3] vs 10.1 months [95% CI, 9.2-10.9], p = 0.564). Conclusions In patients with HER2-positive gastric or GEJ adenocarcinoma, the objective response rate to second-line treatment with ramucirumab plus paclitaxel was significantly higher compared to patients with HER2-negative disease. However, an increased response to treatment was not associated with an improvement in OS.
Full Text
https://link.springer.com/article/10.1007/s10120-021-01276-4
DOI
10.1007/s10120-021-01276-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191425
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links